Company intelligence / Profile preview

Nano Retina

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Nano Retina developed the NR600 System, an active implantable bionic eye designed to restore rudimentary vision in patients with severe visual impairment due to retinal degenerative diseases. The system included a tiny retinal implant and external smart glasses that powered and communicated with the device. Early clinical studies aimed to demonstrate safety and performance but were ultimately discontinued due to lack of investor support; the company ceased operations in spring 2024 before reaching commercialization or late-stage trials.

Therapeutic areas: Ophthalmology
Modalities: DeviceNanotechnology-based implantable device
Industry: Implantable Medical Devices

Partnerships

Collaborated globally with research centers and technology manufacturers

Beyond the preview

Go deeper on Nano Retina.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nano Retina.

Explore the full profile